Agomelatine in the treatment of major depressive disorder: an 8-week, multicenter, randomized, placebo-controlled trial
1. 文件大小不能超过300M, 允许上传文档或压缩包等
2. 请确保上传文献的真实性、完整性，不得对原文做任何修改
注: 所有应助的资源仅供学习交流使用, 不得违反相关法律法规
DOI:
文献链接: https://pubmed.ncbi.nlm.nih.gov/20361916/
其他信息:
SM Stahl, M Fava, MH Trivedi, A Caputo…
The Journal of clinical …, 2010
psychiatrist.com
Objective: To evaluate the efficacy, safety, and tolerability of fixed-dose agomelatine 25 and 50 mg/d in the treatment of outpatients with moderate-to-severe major depressive disorder (MDD) compared to placebo. Method: In this 8-week, multicenter, double-blind, parallel-group trial, patients with DSM-IV–defined MDD were randomly assigned (1: 1: 1) to receive a once-daily dose of agomelatine 25 mg, agomelatine 50 mg, or placebo. The primary efficacy measure was the change from baseline to week 8 in the clinician-rated 17-item Hamilton …
